Two‐year follow‐up of a randomized phase <scp>III</scp> clinical trial of nivolumab vs. the investigator's choice of therapy in the Asian population for recurrent or metastatic squamous cell carcinoma of the head and neck (<scp>CheckMate</scp> 141)
Head & neck